Emanuelle Renck, Caroline Beatriz Zipper, Marcio Rodrigues Fabrino Junior, Luisa Andrea Torres Salgado, Adriel Rowe, Ernani Tiaraju de Santa Helena
{"title":"2021 年在巴西布卢梅瑙接种疫苗预防 COVID-19 引起的严重急性呼吸道综合征患者死亡的有效性。","authors":"Emanuelle Renck, Caroline Beatriz Zipper, Marcio Rodrigues Fabrino Junior, Luisa Andrea Torres Salgado, Adriel Rowe, Ernani Tiaraju de Santa Helena","doi":"10.1590/S2237-96222024v33e2023214.en","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>to analyze the vaccine effectiveness in preventing deaths attributed to severe acute respiratory syndrome due to COVID-19 (SARS/COVID-19) in adults and the elderly, in Blumenau, state of Santa Catarina, Brazil, 2021.</p><p><p>this was a population-based study conducted among individuals aged 20 years and older hospitalized with SARS/COVID-19; each death due to SARS/COVID-19 was considered a \"case\", and every survivor was considered a \"control\"; the association between vaccination status and the outcome of \"death\" was estimated using logistic regression, and vaccine effectiveness was estimated as (1-OR)*100.</p><p><p>The study included 1,756 cases of SARS/COVID-19 (59.2% male, mean age of 56 years, 50.4% with elementary education, 68.4% with comorbidities and 39.1% in intensive care), of whom 398 died (cases) and 1,358 survived (controls); vaccine effectiveness was 74% and 85% (20-59 years old) and 72% and 75% (≥ 60 years old), respectively, for those who were partially vaccinated and fully vaccinated.</p><p><strong>Conclusion: </strong>vaccines proved to be effective in reducing case fatality ratio due to SARS/COVID-19 in individuals ≥ 20 years old.</p>","PeriodicalId":51473,"journal":{"name":"Epidemiologia e Servicos de Saude","volume":"33 ","pages":"e2023214"},"PeriodicalIF":2.5000,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10883351/pdf/","citationCount":"0","resultStr":"{\"title\":\"Vaccine effectiveness in preventing deaths in people with severe acute respiratory syndrome due to COVID-19 in Blumenau, Brazil, 2021.\",\"authors\":\"Emanuelle Renck, Caroline Beatriz Zipper, Marcio Rodrigues Fabrino Junior, Luisa Andrea Torres Salgado, Adriel Rowe, Ernani Tiaraju de Santa Helena\",\"doi\":\"10.1590/S2237-96222024v33e2023214.en\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>to analyze the vaccine effectiveness in preventing deaths attributed to severe acute respiratory syndrome due to COVID-19 (SARS/COVID-19) in adults and the elderly, in Blumenau, state of Santa Catarina, Brazil, 2021.</p><p><p>this was a population-based study conducted among individuals aged 20 years and older hospitalized with SARS/COVID-19; each death due to SARS/COVID-19 was considered a \\\"case\\\", and every survivor was considered a \\\"control\\\"; the association between vaccination status and the outcome of \\\"death\\\" was estimated using logistic regression, and vaccine effectiveness was estimated as (1-OR)*100.</p><p><p>The study included 1,756 cases of SARS/COVID-19 (59.2% male, mean age of 56 years, 50.4% with elementary education, 68.4% with comorbidities and 39.1% in intensive care), of whom 398 died (cases) and 1,358 survived (controls); vaccine effectiveness was 74% and 85% (20-59 years old) and 72% and 75% (≥ 60 years old), respectively, for those who were partially vaccinated and fully vaccinated.</p><p><strong>Conclusion: </strong>vaccines proved to be effective in reducing case fatality ratio due to SARS/COVID-19 in individuals ≥ 20 years old.</p>\",\"PeriodicalId\":51473,\"journal\":{\"name\":\"Epidemiologia e Servicos de Saude\",\"volume\":\"33 \",\"pages\":\"e2023214\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-02-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10883351/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epidemiologia e Servicos de Saude\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/S2237-96222024v33e2023214.en\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Multidisciplinary\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologia e Servicos de Saude","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S2237-96222024v33e2023214.en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}
Vaccine effectiveness in preventing deaths in people with severe acute respiratory syndrome due to COVID-19 in Blumenau, Brazil, 2021.
Objective: to analyze the vaccine effectiveness in preventing deaths attributed to severe acute respiratory syndrome due to COVID-19 (SARS/COVID-19) in adults and the elderly, in Blumenau, state of Santa Catarina, Brazil, 2021.
this was a population-based study conducted among individuals aged 20 years and older hospitalized with SARS/COVID-19; each death due to SARS/COVID-19 was considered a "case", and every survivor was considered a "control"; the association between vaccination status and the outcome of "death" was estimated using logistic regression, and vaccine effectiveness was estimated as (1-OR)*100.
The study included 1,756 cases of SARS/COVID-19 (59.2% male, mean age of 56 years, 50.4% with elementary education, 68.4% with comorbidities and 39.1% in intensive care), of whom 398 died (cases) and 1,358 survived (controls); vaccine effectiveness was 74% and 85% (20-59 years old) and 72% and 75% (≥ 60 years old), respectively, for those who were partially vaccinated and fully vaccinated.
Conclusion: vaccines proved to be effective in reducing case fatality ratio due to SARS/COVID-19 in individuals ≥ 20 years old.